Can genetics improve precision of therapy in diabetes?

Trends in Endocrinology and Metabolism

Volumn 25, Issue 9, 2014, Pages 440-443

  Groop, Leif ^a   Storm, Petter ^a   Rosengren, Anders ^a  

^a LUND UNIVERSITY DIABETES CENTRE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; METFORMIN; SULFONYLUREA DERIVATIVE; THIOZOLIDINEDION; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

DIABETES MELLITUS; DIABETIC PATIENT; EUROPE; GENETIC ANALYSIS; GENETIC HETEROGENEITY; HEALTH CARE COST; HUMAN; NOTE; PHARMACOGENETICS; PRIORITY JOURNAL; QUALITY OF LIFE; BIOAVAILABILITY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GENETIC VARIABILITY; GENETICS; INTESTINE ABSORPTION; METABOLISM; PERSONALIZED MEDICINE; PROCEDURES;

BIOLOGICAL AVAILABILITY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GENETIC VARIATION; HUMANS; HYPOGLYCEMIC AGENTS; INDIVIDUALIZED MEDICINE; INTESTINAL ABSORPTION; METFORMIN; PHARMACOGENETICS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 84906794580     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2014.06.005     Document Type: Note

References (17)

1. Eichelbaum M., et al. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 2006, 57:119-137.
2. Link E., et al. SLCOB1 variants and statin-induced myopathy - a genome wide study. N. Engl. J. Med. 2008, 359:789-799.
3. Pirmohamed M., et al. A randomized trial of genotype-guided dosing of warfarin. N. Engl. J. Med. 2013, 369:2294-2303.
4. Pearson E. Stratified approaches to the management of diabetes. RD Lawrence Lecture. Diabet. Med. 2013, 31:393-398.
5. Pearson E.R., et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir 6.2 mutations. N. Engl. J. Med. 2006, 355:467-477.
6. Mlynarski W., et al. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11. Nat. Clin. Pract. Neurol. 2007, 3:640-645.
7. Pearson E., et al. Genetic cause of hyperglycemia and response to treatment in diabetes. Lancet 2003, 362:1275-1281.
8. Shu Y., et al. Effect of genetic variation in the organic cation transporter OCT1 on metformin action. J. Clin. Invest. 2007, 117:1422-1431.
9. Becker M.L., et al. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet. Genomics 2010, 20:38-44.
10. Zhou K., et al. Common variants near ATM is significantly associated with glycemic response to metformin in type 2 diabetes. Nat. Genet. 2011, 43:117-120.
11. Pernicova I., Korbonits M. Metformin - mode of action and clinical implications for diabetes and cancer. Nat. Rev. Endocrinol. 2014, 10:143-156.
12. Becker M.L., et al. Pharmacogenetics of oral antidiabetic drugs. Int. J. Endocrinol. 2013, 10.1155/2013/686315.
13. 't Hart L.M., et al. The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. Diabetes 2013, 62:3275-3281.
14. Pearson E.R., et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007, 56:2178-2182.
15. Tuomi T., et al. The many faces of diabetes: a disease with increasing heterogeneity. Lancet 2014, 383:1084-1094.
16. Brophy S., et al. Interventions for latent autoimmune diabetes (LADA) in adults. Cochrane Database Syst. Rev. 2011, 10.1002/14651858.CD006165.pub3.
17. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.